Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Amgen : Reports Outline Genetics Study Findings from Amgen (Graphtyper enables population-scale genotyping using pangenome graphs)

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:52pm CET

By a News Reporter-Staff News Editor at Life Science Weekly -- Researchers detail new data in Life Science Research - Genetics. According to news reporting originating from Reykjavik, Iceland, by NewsRx correspondents, research stated, "A fundamental requirement for genetic studies is an accurate determination of sequence variation. While human genome sequence diversity is increasingly well characterized, there is a need for efficient ways to use this knowledge in sequence analysis."

Our news editors obtained a quote from the research from Amgen, "Here we present Graphtyper, a publicly available novel algorithm and software for discovering and genotyping sequence variants. Graphtyper realigns short-read sequence data to a pangenome, a variation-aware graph structure that encodes sequence variation within a population by representing possible haplotypes as graph paths. Our results show that Graphtyper is fast, highly scalable, and provides sensitive and accurate genotype calls. Graphtyper genotyped 89.4 million sequence variants in the whole genomes of 28,075 Icelanders using less than 100,000 CPU days, including detailed genotyping of six human leukocyte antigen (HLA) genes."

According to the news editors, the research concluded: "We show that Graphtyper is a valuable tool in characterizing sequence variation in both small and population-scale sequencing studies."

For more information on this research see: Graphtyper enables population-scale genotyping using pangenome graphs. Nature Genetics, 2017;():. (Nature Publishing Group - www.nature.com/; Nature Genetics - www.nature.com/ng/)

The news editors report that additional information may be obtained by contacting H.P. Eggertsson, deCODE Genetics, Amgen Inc, Reykjavik, Iceland. Additional authors for this research include H. Jonsson, S. Kristmundsdottir, E. Hjartarson, B. Kehr, G. Masson, F. Zink, K.E. Hjorleifsson, A. Jonasdottir, A. Jonasdottir, I. Jonsdottir, D.F. Gudbjartsson, P. Melsted, K. Stefansson and B.V Halldorsson (see also Life Science Research - Genetics).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/ng.3964. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Iceland, Genetics, Reykjavik, Life Science Research.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN
03/22AMGEN : Patent Issued for Administration of Alpha4beta7 Hetero-Dimer-Specific An..
03/22AMGEN : Reports Outline Secondary Hyperparathyroidism Study Findings from Amgen ..
03/15AMGEN : Researchers from Amgen Report New Studies and Findings in the Area of Bi..
03/15AMGEN : New Analyses Show Payer Utilization Management Criteria Deny Access to P..
03/12Praluent lowers risk of death; Sanofi, Regeneron offer lower price
03/08AMGEN : To Present New Data From Repatha® evolocumab Clinical Trials At ACC.18
03/07AMGEN : Announces 2018 Second Quarter Dividend
03/07AMGEN : To Present At the Cowen and Company 38th Annual Health Care Conference
03/07AMGEN : Economic burden of CVD in Saudi Arabia to jump to $9.8bn by 2035
03/06CYTOKINETICS : to Present at March Investor Conferences
More news
News from SeekingAlpha
03/22Rituxan biosimilar captures 80% of British market 
03/21FDA OKs Sun Pharma's Ilumya for plaque psoriasis 
03/20Unum Therapeutics Updates Proposed IPO Terms 
03/20AAM S&P 500 HIGH DIVIDEND VALUE ETF : Should You Ditch The High Yield Dog For T.. 
03/18TOPS OF 44 'SAFER' DIVIDEND NASDAQ E : Comcast By Gain; Vodafone By Yield For Ma.. 
Financials ($)
Sales 2018 22 585 M
EBIT 2018 11 440 M
Net income 2018 8 234 M
Finance 2018 6 263 M
Yield 2018 2,80%
P/E ratio 2018 15,36
P/E ratio 2019 14,14
EV / Sales 2018 5,53x
EV / Sales 2019 5,35x
Capitalization 131 B
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 196 $
Spread / Average Target 7,5%
EPS Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN4.68%131 164
JOHNSON & JOHNSON-6.09%351 989
PFIZER0.30%216 268
NOVARTIS-5.95%212 073
ROCHE HOLDING LTD.-11.12%198 243
MERCK AND COMPANY-2.81%147 455